NDA 212097 · Xeris
Gvoke Kit
Glucagon · Subcutaneous, Intravenous · Antihypoglycemic Agent; Gastrointestinal Motility Inhibitor
Last checked: Nov 20, 2026Latest source record: Mar 14, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Sep 10, 2019
Approved uses
2
Original approval plus efficacy supplements
Registered trials
1,154
249 Phase 3, 171 recruiting
FAERS reports
16
7 serious, 3 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 30, 2026.
GVOKE is an antihypoglycemic agent indicated for subcutaneous use for the treatment of severe hypoglycemia in adult and pediatric patients aged two years and older with diabetes ( 1.1 ) GVOKE VialDx is a gastrointestinal motility inhibitor indicated for intravenous use as a diagnostic aid during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients ( 1.2 ) 1.1 Severe Hypoglycemia in Adult and Pediatric Patients Aged 2 Years and Older with Diabetes GVOKE is indicated for subcutaneous use for the treatment of severe hypoglycemia in adult and pediatric patients aged two and older with diabetes. 1.2 Diagnostic Aid in Adults GVOKE VialDx is indicated for intravenous use as a diagnostic aid during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients.
Therapeutic areas: Gastroenterology and liver
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 14, 2025 Supplement 12 · Efficacy LetterLabel
- Sep 10, 2019 Original approval · Type 3 - New Dosage Form LabelLetterReview
6 products under this application
- GVOKE KIT · GLUCAGON 1MG/0.2ML (1MG/0.2ML) · SOLUTION, SUBCUTANEOUS · Prescription
- GVOKE HYPOPEN · GLUCAGON 0.5MG/0.1ML (0.5MG/0.1ML) · SOLUTION, SUBCUTANEOUS · Prescription
- GVOKE PFS · GLUCAGON 0.5MG/0.1ML (0.5MG/0.1ML) · SOLUTION, SUBCUTANEOUS · Discontinued
- GVOKE VIALDX · GLUCAGON 1MG/0.2ML (1MG/0.2ML) · SOLUTION, INTRAVENOUS · Discontinued
- GVOKE HYPOPEN · GLUCAGON 1MG/0.2ML (1MG/0.2ML) · SOLUTION, SUBCUTANEOUS · Prescription
- GVOKE PFS · GLUCAGON 1MG/0.2ML (1MG/0.2ML) · SOLUTION, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Glucagon" as an intervention, any sponsor and status, largest first.
- High Risk Population of Cardiovascular Disease in Hubei Province Screening and Intervention ProgramPivotal-lookingStatus unknown
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAcademic, hospital or other
NCT05782881 · 16,000 participants (planned) · Start Jan 15, 2023 · Primary completion Dec 31, 2023
Drug: Statin · For: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Coronary Disease
Sites: Enshi, China; Ezhou, China; Huanggang, China · 107 sites in all
- A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With ObesityPivotal-lookingActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT05556512 · 15,374 participants · Start Oct 11, 2022 · Primary completion Oct 2027
Drug: Tirzepatide; Placebo · For: Obesity; Overweight
Sites: Gilbert, Arizona; Mesa, Arizona; Phoenix, Arizona · 672 sites in all
- A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 DiabetesPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT04255433 · 13,299 participants · Start May 29, 2020 · Primary completion Jun 12, 2025
Drug: Tirzepatide; Dulaglutide · For: Type 2 Diabetes Mellitus
Sites: Birmingham, Alabama; Concord, California; Covina, California · 635 sites in all
- Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes MellitusPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT02465515 · 9,463 participants · Start Jul 1, 2015 · Primary completion Feb 20, 2018
Drug: Albiglutide 30 mg; Albiglutide 50 mg and 1 more · For: Diabetes Mellitus
Sites: Birmingham, Alabama; Mobile, Alabama; Chandler, Arizona · 607 sites in all
- Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome ResultsPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT01179048 · 9,341 participants · Start Aug 31, 2010 · Primary completion Dec 17, 2015
Drug: liraglutide; placebo · For: Diabetes; Diabetes Mellitus, Type 2
Sites: Alabaster, Alabama; Birmingham, Alabama; Huntsville, Alabama · 428 sites in all
- A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 DiabetesPivotal-lookingCompleted
GRADE Study GroupAcademic, hospital or other
NCT01794143 · 7,850 participants · Start May 2013 · Primary completion Apr 30, 2021
Drug: Sulfonylurea (glimepiride); DPP-4 inhibitor (sitagliptin) and 2 more · For: Type 2 Diabetes; Comparative Effectiveness of Glycemia-lowering Medications
Sites: Birmingham, Alabama; Phoenix, Arizona; San Diego, California · 36 sites in all
- PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 DiabetesPivotal-lookingRecruiting
Brigham and Women's HospitalAcademic, hospital or other
NCT05390892 · 6,000 participants (planned) · Start Sep 26, 2022 · Primary completion Mar 1, 2029
Drug: SGLT2 inhibitor; GLP-1 receptor agonist · For: Type2Diabetes; ASCVD
Sites: Huntsville, Alabama; Scottsdale, Arizona; Los Angeles, California · 36 sites in all
- A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)Pivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07165028 · 4,500 participants (planned) · Start Oct 15, 2025 · Primary completion Aug 2030
Drug: Tirzepatide; Retatrutide and 1 more · For: Metabolic Dysfunction-Associated Steatotic Liver Disease
Sites: Tuscaloosa, Alabama; Chandler, Arizona; Gilbert, Arizona · 563 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- blood glucose decreased3
- constipation2
- death2
- dizziness2
- screaming2
- abdominal pain1
- abdominal pain upper1
- aphasia1
- arthralgia1
- atrial fibrillation1
- blood creatinine increased1
- blood pressure systolic decreased1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2006 | 1 |
| 2014 | 1 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 3 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.
Xie Z, Zheng G, Liang Z, et al. · Metabolism 2024 · Systematic Review, Network Meta-Analysis
- Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis.
Chiang CH, Jaroenlapnopparat A, Colak SC, et al. · Gastroenterology 2025 · Systematic Review, Meta-Analysis
- Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis.
Berg S, Stickle H, Rose SJ, et al. · Obes Rev 2025 · Meta-Analysis, Systematic Review
- Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes mellitus.
Tsukamoto S, Tanaka S, Yamada T, et al. · Diabetes Obes Metab 2024 · Systematic Review, Network Meta-Analysis
- The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials.
Liu Y, Ruan B, Jiang H, et al. · Am J Clin Nutr 2023 · Meta-Analysis, Systematic Review
- Safety and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in patients with weight regain or insufficient weight loss after metabolic bariatric surgery: A systematic review and meta-analysis.
Esparham A, Mehri A, Dalili A, et al. · Obes Rev 2024 · Meta-Analysis, Systematic Review
Sponsor: Xeris · Also marketed as Gvoke Hypopen, Gvoke Pfs, Gvoke Vialdx
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.